|
|
Vaccine Detail
|
B7.1/IL-2 Leukaemia Cell Vaccine |
| Vaccine Information |
- Vaccine Name: B7.1/IL-2 Leukaemia Cell Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Live, attenuated vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: B7.1 (NCT02493829)
- Immunization Route: Other
- Description: A whole-cell cancer vaccine, containing human acute myeloid leukemic (AML) blasts that have been genetically engineered to express a B7.1/IIL-2 fusion protein. It uses B7.1 (CD80)/IL-2 immune gene therapy for high risk MDS RAEB-2 and acute myeloid leukaemia (AML) patients who are unsuitable for an allogeneic haematological stem cell transplant. (NCT02493829)
|
| Host Response |
|
|
| References |
NCT02493829: B7.1/IL-2 Leukaemia Cell Vaccine for Non-Transplant AML RFUSIN2-AML2 (NTX) [https://clinicaltrials.gov/study/NCT02493829]
|
|
